CHICAGO — The suspense will end Friday when results from four highly anticipated clinical trials of nivolumab and pembrolizumab will be released at the American Society of Clinical Oncology meeting.

Both drugs are already-available programmed death inhibitors, and curiosity has been building about early clinical trials of nivolumab (Opdivo, Bristol-Myers Squibb Company) in advanced liver disease and pembrolizumab (Keytruda, Merck) in head and neck cancer.

The Medscape Oncology news team is traveling today to Chicago and will report the findings and all the latest news from McCormick Place.

Among the highlights on Friday will be details from the phase 3 trial of nivolumab in non-small cell lung cancer. Topline results released in January quickly led to the approval of the first immunotherapy for lung cancer by the US Food and Drug Administration.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.